The GCS Project has filed with the IRS to become a 501c3. As per the IRS letter, we expect to receive our approval letter by December 1, 2017. Any donation made to the GCS Project during this application period will be tax deductible.
Obtaining 501c3 status will enable the GCS Project to become eligible for grants and other public and private allocations available only to IRS-recognized, 501c3 organizations. In addition, if an organization has obtained 501(c)(3) tax exempt status, an individual’s or company’s charitable contributions to this entity are tax-deductible. In addition, 501c3 status confers a public legitimacy or IRS recognition.
Why does the GCS Project need to become a 501c3?
Currently, we direct donors to direct their contributions to the carcinosarcoma research fund at Mass General Cancer Center. The GCS Project will continue to support the brilliant work being done at MGH. Moving forward, the GCS Project will fund new and innovative research initiatives to find a cure for this monster. It is our goal to support GCS research at several major cancer centers and encourage collaboration among scientists.
For example, now that Dr. Birrer is moved to the University of Alabama, the GCS Project will have researchers at two sites working for us. There are other researchers who have become interested in this research as a result of some of the ground-breaking findings from this project at MGH. We want to support any research that will enable women with GCS to conquer this cancer and live longer. The 501c3 IRS designation will enable us to move forward. The change is supported by MGH and Dr. Birrer.
THIS IS fantastic news!
The GCS Project has been approved by the IRS to be a 501c3 organization.
Thanks to all who have made generous donations that enable us to move this important work forward.
Did you mean that donations are tax deductible after May 2017? Or is 2018 accurate?
Deductions made after May 17, 2018 are tax deductible. It is retroactive to when the application was made. (Prior to May 2018, all donations went to Mass General Cancer Center.)
Thanks for your inquiry
Yes it is May 2017 not May 2018.
thanks for picking that up.
Clinical trials are currently being offered at the University of Arkansas for Medical Sciences (UAMS). Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single… Read More »
Clinical trials are currently being offered at the University of Alabama at Birmingham. Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in… Read More »
Clinical trials are currently being offered at Medical University of South Carolina (MUSC) Health Care in Charleston SC. A Phase II/III Study of Paciltaxel/Carboplatin alone, or combined with either Trastuzumab… Read More »